Personalised blood test could help predict which lung cancers might return

byGraeme Sneddon| News1 April 2022Patients who are at a higher risk of their lung cancer returning can be identified by a personalised blood test that is performed after treatment, accordi

Updated on: December 19,2023 24

Personalised blood test could help predict which lung cancers might return

byGraeme Sneddon| News1 April 2022Patients who are at a higher risk of their lung cancer returning can be identified by a personalised blood test that is performed after treatment, accordi

Updated on:December 19,2023 24

Chinese medicine ingredients found to generate autophagic flux to suppress tumor progression in gastric cancer

byScience China PressActivation of Beclin-1 by piceatannol promotes autophagic flux in GC cells, and combined with everolimus, triggers autophagic death, ultimately inhibiting tumor progression,

Updated on: December 21,2023 10

Chinese medicine ingredients found to generate autophagic flux to suppress tumor progression in gastric cancer

byScience China PressActivation of Beclin-1 by piceatannol promotes autophagic flux in GC cells, and combined with everolimus, triggers autophagic death, ultimately inhibiting tumor progression,

Updated on:December 21,2023 10

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on: December 20,2023 19

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on:December 20,2023 19

Acute leukemia patients treated with common therapy have increased risk for heart failure

byPerelman School of Medicine at the University of PennsylvaniaPatients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heigh

Updated on: December 22,2023 17

Acute leukemia patients treated with common therapy have increased risk for heart failure

byPerelman School of Medicine at the University of PennsylvaniaPatients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heigh

Updated on:December 22,2023 17

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on: December 21,2023 18

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on:December 21,2023 18

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on: December 17,2023 10

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on:December 17,2023 10

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on: December 21,2023 10

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on:December 21,2023 10

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on: October 17,2023 63

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on:October 17,2023 63

Mapping oesophageal cancer genes leads to new drug targets

byCancer Research UK| News4 February 2019Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail – unveiling that more than half could be targeted by

Updated on: December 19,2023 14

Mapping oesophageal cancer genes leads to new drug targets

byCancer Research UK| News4 February 2019Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail – unveiling that more than half could be targeted by

Updated on:December 19,2023 14

Targeting enzyme could alleviate muscle wasting for cancer patients

byUniversity of Texas Health Science Center at HoustonCredit: Pixabay/CC0 Public DomainTargeting a specific enzyme in the muscle could help cancer patients preserve muscle mass and potentially p

Updated on: December 19,2023 8

Targeting enzyme could alleviate muscle wasting for cancer patients

byUniversity of Texas Health Science Center at HoustonCredit: Pixabay/CC0 Public DomainTargeting a specific enzyme in the muscle could help cancer patients preserve muscle mass and potentially p

Updated on:December 19,2023 8

Trial supports radiotherapy and cisplatin remaining as the standard of care for p16+ oropharyngeal cancer

by NRG OncologyCredit: Pixabay/CC0 Public DomainThe NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III portion of the study. The ph

Updated on: October 21,2024 0

Trial supports radiotherapy and cisplatin remaining as the standard of care for p16+ oropharyngeal cancer

by NRG OncologyCredit: Pixabay/CC0 Public DomainThe NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III portion of the study. The ph

Updated on:October 21,2024 0

New study supports extending cervical screening intervals for people who test negative for HPV

byAlice Davies| Analysis1 June 2022Normal squamous epithelial cells from the cervix under the microscopeIn January, we wrote about thechanges to the cervical screening programme in W

Updated on: December 19,2023 23

New study supports extending cervical screening intervals for people who test negative for HPV

byAlice Davies| Analysis1 June 2022Normal squamous epithelial cells from the cervix under the microscopeIn January, we wrote about thechanges to the cervical screening programme in W

Updated on:December 19,2023 23